This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Preventice Progresses Toward Commercial Availability Of Its BodyGuardian Remote Patient Monitoring System™

MINNEAPOLIS, Feb. 25, 2013 /PRNewswire/ -- By all industry accounts, interest in remote patient monitoring is expected to remain strong in the coming years, as hospital readmission penalties in the United States take effect in 2013, and as mHealth technologies become more pervasive in the care delivery system, according to a report from Berg Insights. Berg analysts estimate that 2.8 million people are currently monitored for a variety of conditions outside the clinical setting. This number is expected to continue its upward trajectory, with cardiac rhythm management, sleep therapy and telehealth becoming the most significant categories for remote monitoring devices by 2017.

Preventice, Inc., a leading developer of mHealth solutions, including the BodyGuardian Remote Patient Monitoring System (BodyGuardian RMS) is poised to capitalize on this opportunity through its unique approach to strategic partnerships and its proprietary technology platform. Meanwhile, clinical trials are underway in the United States and Europe to quantify the impact of the BodyGuardian RMS on clinical care delivery.

In good company: Strategic partnerships According to Jon Otterstatter, co-founder, president and CEO of Preventice, the company has established an enviable ecosystem of partners that have allowed it to build a remote monitoring platform that is secure, reliable and scalable.

"From day one, we have made it a priority to affiliate the Preventice brand with leaders in health care, wireless devices, sensor technology, and production processes," said Otterstatter. "As a result, we have built a remote monitoring platform that meets the most stringent privacy and security standards, that is reliable in a variety of clinical and non-clinical settings and that exceeds the usability expectations of today's sophisticated consumers."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,364.64 -314.06 -1.78%
S&P 500 2,032.74 -24.35 -1.18%
NASDAQ 4,696.2230 -75.54 -1.58%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs